IDEXX Laboratories delivered a solid QQ4 2024 performance, underpinned by resilient demand for companion-animal diagnostics and expanding water testing offerings. Revenue of USD 954.3 million marked a 5.84% year‑over‑year increase but a 2.18% quarter‑over‑quarter decline, reflecting a modest sequential slowdown. The company maintained a durable margin profile, with gross margin of 59.8% and operating margin of 27.4%, supported by favorable product mix, pricing discipline, and continued cost discipline. Net income rose 11.12% year over year to USD 216.1 million, yielding an EPS of USD 2.63 (diluted USD 2.62). Cash flow generation remained robust, with cash from operations of USD 262.0 million and free cash flow of USD 222.8 million, enabling continued capital allocation activities including USD 245.99 million in share repurchases, partially offset by net debt accumulation and debt repayments during the period.